Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis
Authors:
Open Access
- 8 February 2016
- journal article
- research article
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 23 (2) , 71-79
Abstract
Purpose: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents including ranibizumab and aflibercept are used to treat patients with ocular disorders such as neovascular age-related macular degeneration (nAMD); however, the injections are associated with rare instances of severe ocular inflammation. This study compared severe ocular inflammation rates in patients treated with ranibizumab versus aflibercept. Methods: United States physician-level claims data covering an 18-month period for each therapy were analyzed. The primary analysis compared severe ocular inflammation event rates per 1000 injections. Sensitivity and subgroup analyses evaluated the impact of factors including intraocular surgery, intravitreal antibiotic administration, and previous intravitreal injections. Results: The analysis included 432,794 injection claims (ranibizumab n = 253,647, aflibercept n = 179,147); significantly, more unique severe ocular inflammation events occurred in patients receiving aflibercept than ranibizumab (1.06/1000 injections, 95% confidence interval [CI], 0.91–1.21, vs. 0.64/1000 injections, 95% CI 0.54–0.74; p < 0.0001). Comparable results were observed for analyses of patients who had undergone glaucoma or cataract surgeries, had antibiotic-associated endophthalmitis, had non-antibiotic-associated endophthalmitis, and were non-treatment-naive. In contrast, no significant differences in severe ocular inflammation claims were recorded in treatment-naive patients who had no record of anti-VEGF treatment in the 6 months preceding the index claim. No significant change occurred in the rate of severe ocular inflammation claims over time following ranibizumab treatment. Conclusions: Severe ocular inflammation was more frequent following intravitreal injection with aflibercept than with ranibizumab during routine clinical use in patients with nAMD. This highlights the importance of real-world, post-approval, observational monitoring of novel medicines, and may aid clinical decision-making, including choice of anti-VEGF agent.Keywords
Funding Information
- Novartis Pharma AG, Basel, Switzerland
This publication has 48 references indexed in Scilit:
- Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic ReviewPLOS ONE, 2013
- Risk Factors for Acute Endophthalmitis following Cataract Surgery: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-Naïve EyesInvestigative Ophthalmology & Visual Science, 2013
- Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UKBritish Journal of Ophthalmology, 2013
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmology, 2011
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabEye, 2011
- Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitisClinical Ophthalmology, 2010
- Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not RequiredArchives of Ophthalmology (1950), 2009
- Postoperative infection in penetrating versus non-penetrating glaucoma surgeryBritish Journal of Ophthalmology, 2009